Key considerations for protein targets: Use ideal body weight (IBW) or adjusted body weight for calculations, not current weight in patients with obesity Distribute protein across meals rather than concentrating in one sitting Monitor for signs of inadequate intake: fatigue, weakness, hair loss, or poor wound healing Reassess needs every 36 months as weight changes Consult with a registered dietitian for personalized recommendations GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists exert their appetite-suppressing effects through multiple mechanisms
CLA Active Blend
Fertil Steril 2017;107(4):833839
doi: 10.1056/NEJMp2400978 Summary Keywords GIP, GLP-1, GLP-1RA, tirzepatide, diabetes, obesity, cardiovascular disease Citation Liu QK (2024) Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Large molecule conjugation modification Dulaglutide Dulaglutide is a long-acting GLP-1 receptor agonist that employs Fc-fusion protein technology to achieve prolonged systemic exposure
What to Tell Your Healthcare Provider If youre experiencing persistent lumps, rash, or redness after a GLP-1 injection or if theyre simply becoming bothersome contact your healthcare provider
